Antimicrobial peptides under clinical investigation
Peptide Science · 2019-09 · 111 (5)
DOI: 10.1002/pep2.24122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Peptide Science, online erschienen am 03.06.2019. Verfasst von Hye Been Koo und 1 weiteren Autor:innen. Die Arbeit wurde bisher 366-mal zitiert (Crossref) und nennt 113 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Overuse of conventional antibiotics as well as the slow pace of new antibiotic drug development leads to antimicrobial resistance (AMR). Because infections with multi‐drug resistant (MDR) pathogens have become a public health issue, the need for a novel class of antibiotics is urgent. Recently, antimicrobial peptides (AMPs) have emerged as a promising platform to fight against MDR bacteria ensuring broad‐spectrum antimicrobial activity and relatively low resistance emergence. Currently, a number of AMPs are undergoing clinical and preclinical trials against various infectious diseases. This review lists the 36 AMPs (27 clinical and 9 preclinical) with brief information about their origin, structure, mechanism, and development status. From the examples of AMPs under clinical investigation, we categorized several improvement strategies and highlighted directions for the future design of AMPs.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Koo, H. B., & Seo, J. (2019). Antimicrobial peptides under clinical investigation. Peptide Science, 111(5). https://doi.org/10.1002/pep2.24122
Vancouver
Koo HB, Seo J. Antimicrobial peptides under clinical investigation. Peptide Science. 2019;111(5). doi:10.1002/pep2.24122
BibTeX
@article{Koo2019,
author = {Koo, Hye Been and Seo, Jiwon},
title = {Antimicrobial peptides under clinical investigation},
journal = {Peptide Science},
year = {2019},
volume = {111},
number = {5},
doi = {10.1002/pep2.24122}
}
EUVIMED